Spring in the winter: Spring Bank Pharmaceuticals files for a $58 million IPO

Spring Bank Pharmaceuticals, which is developing a protein-modulating small molecule platform to treat viral diseases, filed on Tuesday with the SEC to raise up to $58 million in an initial public offering. 


The Milford, MA-based company, which was founded in 2002 and booked $1 million in sales for the 12 months ended September 30, 2015, plans to list on the Nasdaq under the symbol SBPH. Spring Bank Pharmaceuticals filed confidentially on 8/3/2015. William Blair, Wedbush PacGrow and BTIG are the joint bookrunners on the deal. No pricing terms were disclosed.

Share on Google Plus

About Jessica Hornberger

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.